Press Releases :: Sonnet BioTherapeutics, Inc. (PURR)

Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination

Trading on The Nasdaq Capital Market under the ticker symbol “PURR”

Full Press Release Here

Nov 06, 2024 8:30am EST

Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates

Oct 17, 2024 8:45am EDT

Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq

Oct 09, 2024 8:45am EDT

Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India

Oct 04, 2024 8:30am EDT

Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs

Sep 30, 2024 9:00am EDT

Sonnet BioTherapeutics Announces Launch of CEO Corner Platform

Sep 25, 2024 8:30am EDT

Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split

Sep 18, 2024 8:30am EDT

Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors

Sep 04, 2024 9:15am EDT

Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series

Aug 19, 2024 8:45am EDT

Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer

Aug 14, 2024 8:35am EDT

Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

1
2
3
4
5
6
7
8
9
10
...13